ArticleDeutsches Arzteblatt international2011
Prescription prevalence and continuing medication use for secondary prevention after myocardial infarction: the reality of care revealed by claims data analysis.
Article in Deutsches Arzteblatt international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year.Drugs & aging · 2014Trial
- Use of big data from health insurance for assessment of cardiovascular outcomes.Frontiers in artificial intelligence · 2023Review
- Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases.Journal of clinical medicine · 2021Article
- A retrospective cohort study examining secondary prevention post stroke in primary care in an Asian setting.BMC family practice · 2021Article
- New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Participation in disease management programs and major adverse cardiac events in patients after acute myocardial infarction: a longitudinal study based on registry data.BMC cardiovascular disorders · 2021Article
- Article
- Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data.BMC health services research · 2020Observational
- Article
- Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) - What Benchmark are We Aiming at in Continuing Medical Education (CME)?Journal of European CME · 2020Article
- Metamizole and the risk of drug-induced agranulocytosis and neutropenia in statutory health insurance data.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Long-Term Risk Factor Control After Myocardial Infarction-A Need for Better Prevention Programmes.Journal of clinical medicine · 2019Review
- Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan.BMC cardiovascular disorders · 2019Article
- Article
- Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.Vascular health and risk management · 2019Article
- Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? : Results from the Dyslipidemia International study II.Wiener klinische Wochenschrift · 2018 · on this mapObservational
- Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany.Pharmacology research & perspectives · 2018Article
- Comparing routine administrative data with registry data for assessing quality of hospital care in patients with myocardial infarction using deterministic record linkage.BMC health services research · 2016Article
- Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis.Cardiovascular diabetology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines recommend using aspirin, clopidogrel, beta-blockers, statins, and angiotensin converting enzyme (ACE) inhibitors after acute myocardial infarction (AMI). Although there is evidence that patients often stop taking these medications prematurely, long-term data reflecting the actual reality of care are lacking. We studied prescription prevalence and treatment persistence of secondary prevention in patients who had an AMI by analyzing relevant claims data from a German sickness fund, the Techniker Krankenkasse (these data are not necessarily representative of the entire German population).
methodsInsurees who were discharged from the hospital between 2001 and 2006 with AMI as their main discharge diagnosis were classified as users or non-users of each of the types of drug listed above on the basis of the prescriptions that they obtained in the first 90 days after they left the hospital. Treatment persistence was statistically assessed with survival analysis. Switches from one drug class to another were not examined.
resultsOf 30,028 AMI patients, 82% were initially prescribed a beta-blocker, 73% a statin, 69% an ACE inhibitor, 66% aspirin (without self-medication), and 61% clopidogrel. Five years after discharge, 10% of the patients for whom aspirin was initially prescribed were still taking it; the corresponding figures for the other drug classes were 17% for statins, 31% for ACE inhibitors, and 36% for beta-blockers. The greatest drop in treatment persistence occurred approximately one year after the AMI.
conclusionTreatment persistence with recommended medication after AMI is still in need of improvement. Patient education should start as soon as possible after infarction, because the greatest drops in medication use appear to occur within one year after AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.